Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

April 5, 2019April 5, 2019

Fertility Treatments Do Not Affect Child’s Risk for Developing Juvenile Idiopathic Arthritis, Large Study Finds

News

Children who were conceived by women using fertility treatments do not show an increased risk for juvenile idiopathic arthritis (JIA), a large Danish population study reports. The study, “Risk ... Read more

January 18, 2019January 18, 2019

Walking Problems May Persist in Children Even as Inflammation Eases Over Time, Study Finds

News

Knee and ankle joint inflammation and walking difficulties in children and adolescents with juvenile idiopathic arthritis (JIA) tends to decrease and stabilize in the first five years after diagnosis, ... Read more

January 15, 2019January 15, 2019

Boys with Early JIA Have Greater Deficit of IGF-1 than Girls, Study Shows

News

Boys with early juvenile idiopathic arthritis (JIA) have lower levels of insulin-like growth factor 1, a growth hormone, compared to age-matched girls in the same stage of early disease, ... Read more

September 7, 2018September 7, 2018

Humira’s Safety in Children With JA, Other Diseases Comparable to That in Adults, Study Suggests

News

The safety profile of Humira (adalimumab) in children with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis, and Crohn’s disease is similar to that in adults, a large analysis of ... Read more

August 6, 2018August 6, 2018

Naproxen-based Combo May Help Reduce Risk of Gastric Ulcers in JIA Teens, Phase 4 Trial Shows

News

Results from a six-month, Phase 4 trial support a combination therapy of the anti-inflammatory naproxen together with an immediate-release form of esomeprazole to reduce the risk of gastric ulcers ... Read more

July 23, 2018July 23, 2018

Low Number of Regulatory B-cells May Help Fuel Juvenile Idiopathic Arthritis, Study Suggests

News

Low numbers of a group of immune cells — called regulatory B-cells — that help to control inflammation may underlie the development of juvenile idiopathic arthritis (JIA), early research ... Read more

June 1, 2018June 1, 2018

Lupin Seeking Marketing Approval in Europe for YLB113, Etanercept Biosimilar

News

The European Medicines Agency has accepted for review Lupin’s marketing authorization application seeking approval to market the company’s biosimilar therapy of etanercept, called YLB113. Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ... Read more

May 21, 2018May 21, 2018

Actemra Treatment Linked to Disease Remission in Systemic JIA, German Registry Shows

News

Treatment with Actemra (tocilizumab) is linked to favorable outcomes, namely disease inactivation and remission, in patients with systemic juvenile idiopathic arthritis, according to an analysis of a German autoinflammatory ... Read more

March 26, 2018March 26, 2018

Checklist Identifies Kids with Rheumatic Diseases Who Can Receive Chickenpox Vaccine, Study Says

News

Researchers have determined that the chickenpox vaccine is safe for children with juvenile chronic arthritis and other rheumatic diseases undergoing intensive immunosuppressive therapy, as long as they complete a pre-vaccination ... Read more

February 16, 2018February 16, 2018

American College of Rheumatology Drops Its Early Caution, Supports Biosimilars

News

The American College of Rheumatology has issued a white paper supporting the use of biosimilars as treatments for rheumatic diseases. It had urged caution when the first biosimilars for these ... Read more

Pin It on Pinterest